ALBANY, N.Y. & MILWAUKEE--(BUSINESS WIRE)--GE (NYSE: GE) today announced it has entered into a new worldwide licensing agreement with Bionime, a global leader in biotechnology medical testing, to provide new GE-branded solutions for the diabetes market.
